Durvalumab is a medication used to treat cancer of the lungs, bladder, or urinary tract.
It is an anti-PD-1 and PD-L1 monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 receptor. It is sometimes given when the cancer has spread to other parts of the body or cannot be removed with surgery, or when other treatments did not work or have stopped working.
Durvalumab causes your immune system to attack tumor cells, but it could also attack healthy organs and tissues in your body.
This could lead to serious or life-threatening side effects on your lungs, liver, pancreas, kidneys, intestines, thyroid, or adrenal glands.
.
Ann: FDA Fast Track Designation Granted for VAXINIA Trial Program, page-409
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
28.8¢ |
Change
0.023(8.49%) |
Mkt cap ! $83.66M | |||
| Open | High | Low | Value | Volume |
| 26.5¢ | 30.0¢ | 26.5¢ | $500.8K | 1.775M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 193018 | 28.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.0¢ | 32366 | 10 |
View Market Depth
| Last trade - 12.54pm 13/08/2025 (20 minute delay) ? |
| IMU (ASX) Chart |